Send the following on WhatsApp
Continue to Chathttps://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/Phase-III-trial-demonstrated-Jardiance-is-the-first-SGLT2-inhibitor-to-show-statistically-signific-42495618/?utm_source=whatsapp&utm_medium=social&utm_campaign=share